Tag Archive for: NEPC
Phase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPreclinical: Targeting NSD2, a Promising Strategy Against Treatment-Induced Neuroendocrine Prostate Cancer
/0 Comments/in Preclinical Research/by MaxNew Hope for Neuroendocrine Prostate Cancer: Targeting Mitochondrial HSP60
/0 Comments/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Phase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC June 20, 2025
- Phase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer June 20, 2025
- Real-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment June 20, 2025
- Phase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer June 19, 2025